Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial

BACKGROUND: Past clinical trials of docosahexaenoic Acid (DHA) supplements for the prevention of Alzheimer's disease (AD) dementia have used lower doses and have been largely negative. We hypothesized that larger doses of DHA are needed for adequate brain bioavailability and that APOE4 is assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Arellanes, Isabella C., Choe, Nicholas, Solomon, Victoria, He, Xulei, Kavin, Brian, Martinez, Ashley E., Kono, Naoko, Buennagel, David P., Hazra, Nalini, Kim, Giselle, D'Orazio, Lina M., McCleary, Carol, Sagare, Abhay, Zlokovic, Berislav V., Hodis, Howard N., Mack, Wendy J., Chui, Helena C., Harrington, Michael G., Braskie, Meredith N., Schneider, Lon S., Yassine, Hussein N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502665/
https://www.ncbi.nlm.nih.gov/pubmed/32690472
http://dx.doi.org/10.1016/j.ebiom.2020.102883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502665/
https://www.ncbi.nlm.nih.gov/pubmed/32690472
http://dx.doi.org/10.1016/j.ebiom.2020.102883

Ejemplares similares